Search the Video Library

Filter by Date

Displaying Results 121 - 122 of 122

UCLA Med Center's Dr. Eddie Garon discusses the open question of the optimal duration of ongoing treatment with immunotherapy for lung cancer.

¿Cuáles son los riesgos y beneficios de ibrutinib y de idelalisib? ¿Cómo manejamos los efectos secundarios de los nuevos inhibidores de la tirosina cinasa?

GRACE sat down with Dr. Marco Ruiz to discuss "What are the risks and benefits of Ibrutinib and Idelalisib?" for our continuing video series with our Spanish speaking faculty on updates in blood cancer treatments.